Protocol Ledger

NCT05551117 · Phase II · TERMINATED

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Interventional Phase II clinical trial protocol NCT05551117 sponsored by MacroGenics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-13 Enrollment: 192 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05551117
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)192 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05551117
Protocol FieldVerified Registry Value
NCT IdentifierNCT05551117
Consolidated Lead SponsorMacroGenics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment192 participants (ACTUAL)
Registered Start Date2023-06-13
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05551117
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->
Carolina Urologic Research CenterMyrtle Beach, SCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI